Investigational therapy indicated for the treatment of systemic sclerosis.
Certa Therapeutics revealed in a company press release that the FDA has permitted orphan drug designation for FT011, its investigational therapy for the treatment of systemic sclerosis (scleroderma). This designation is granted for investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US.
"We are very pleased that the FDA has granted Orphan Drug Designation to FT011 which we believe highlights the urgent need for innovation and new therapeutic options for scleroderma patients" said Darren Kelly, CEO, founder, Certa Therapeutics. "This designation represents an important milestone in the development of FT011, which has the potential to establish first-in-class clinical benefits by precisely targeting the root cause of fibrosis and offer treatment across multiple organs within these patients."
Reference: Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis. PR Newswire. October 23, 2023. Accessed October 24, 2023. https://www.prnewswire.com/news-releases/certa-therapeutics-ft011-granted-us-fda-orphan-drug-designation-for-the-treatment-of-systemic-sclerosis-301961921.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.